Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
@lazypunter, could you perhaps explain what you meant by this statement back in June and also similar statements though August: "However, if you are researched , patient and able to afford the luxury of giving Avacta the time it needs, the prize money will be secured ..it will not do it in days ,weeks or months perhaps , as the race is a long one but if what I have read, seen on video and believe is true, Avacta will cut through the field and deliver the results we hope for .LP"
I suspect that you are no longer invested as you claim to be, which would be quite a shame when Avacta cuts through the field and delivers...
You've certainly changed your tune for back in August Lazypunter. Please also clarify whether you do your own research as you've previously suggested or whether you take your info from those you have criticised today? I'm confused.
Part of your August post:
"but the largest shareholding in my portfolio in the CV , Oncology and COPD race, is on Avacta..Why?...Its all in today's RNS and if tomorrow or next week follows the same path after other great RNS , this share will retrace once again...whatever, the outcome, I now intend to fill my boots with more Avacta, as we have the form in the book, to allow us to win the prize waiting for us, but before we can do that we have to ensure everything is right and all that is right, is completed away from the public gaze, as we cannot get this wrong, we only have one chance to get it right and AL knows this and so should others here."
Either way, good luck with your decisions. Patience has been key and I'm certain that patience will be rewarded.
Given the doubtless huge numbers of undiagnosed illnesses that will have accumulated over the last 12 months, you would certainly hope that the review of our AVA6000 application could certainly be completed by MHRA prior to February rather than any later. The potential benefits of getting this trial underway are almost unimaginable, so if they can review data from a vaccine this quickly then they should certainly be able to review a CTA just a s quickly.
That said, news on BAMS and then on 1 or 2 LFDs is due some time soon, so plenty to look forward to in the early New Year.
What we are aiming for is a very precise delivery system for existing chemo drugs, which will allow for greater more frequent dosage with little to no side effects as the system would only target the cancer cells.....probably over simplifying it there, but you get my drift. It would be absolutely transformational for cancer outcomes.
I also hope BAMS is part of this however there is one other MS test being developed for Covid and it's the MAP Science Maldi-TOF so it could well be that they are involved. There has however been nothing online to say that MAP Science are involved with any government program so perhaps nothing to do with them. In addition, Avacta BAMS news is being kept very quiet by all parties, so there's every chance that they will be involved...certainly sounds that way when you read the last RNS and listen to Alastair's tone in today's interview.
Anyway, hopefully AVA6000 news first (Wed/Thurs this week or next) and then lots of Covid diagnostic updates early next year.
Govt will have no choice but to spend more on tests as testing is and will remain key in the battle against this virus. Until such time as mass vaccination has taken place across the globe, every country in the world will require testing. This is clearly why Avacta are continuing to work towards an outcome that produces solutions that can be used and can be trusted to give the most accurate results.
The pain and frustration felt by many will fade away into a distant memory when we finally do get the big news. The UK government and many others around the globe will buy all we can produce. The good news is that no other country seems to have been able to produce what we all now like to term a "gold standard" LFT, so it seems that the hurdles being overcome by Avacta are just as high elsewhere around the globe.
Good luck to all who remain invested and also to those who take up the opportunity at today's bargain price. The clock is still ticking so just a matter of time and patience.
Avacta do not seem to be the best worded RNS you'll come across...I think that's the general consensus. It often seems that we need to read between the lines and work out what is being said by not being said. For example "we have made significant commercial progress for all of our coronavirus testing solutions".
Having told us that they would continue to develop a saliva LFT in tandem with anterior nasal, could the above statement be telling us that as well as BAMS, Elisa and anterior nasal LFT, we are also likely to have commercial deals on a saliva LFT. Why else would you use "all of our coronavirus testing solutions".
I suppose it's similar to the comment about BAMS evaluation which is now is now referred to as "our clinical evaluation" whereas it was previously referred to as "a clinical evaluation" and furthermore it was described as "is ongoing at two UK clinical sites that Avacta has established" whereas it was previously being evaluated "at several sites in the UK." As has been mentioned on here earlier, I think we can deduce that the Condor evaluation must be complete, with the outcome now pending.
Similarly, I believe that AVA6000 not being mentioned as it has been in all other recent updates, can also lead us to an assumption that news on the CTA will be here between now and 31st December.
Time will tell.
They still have massive supplies of the Innova test, so no reason not to make use of it until alternatives arrive. They know they did not spend wisely with Innova, so using it multiple times on one subject will limit false results, but will more importantly help them avoid ever more criticism were they to simply leave them to gather dust while waiting on better tests. Step in Avacta very soon.
Merchantbanker, I do hope that your ODX and other investments come good. I suspect quite a few people are invested in more than one Covid play. I know that I am. What I don't understand is why anyone who is not in a particular stock would choose to keep posting negatively on that stock. I doubt many people will adjust their strategy based on your posts. Save your energy or join the fun and grab a few AVCT as well.
The first delay was a delay to the closure date for submission of tenders from early/mid November to late November. The second delay was after the tender closed, they announced an extension to the date on which notices of intention to award would be sent from some time last week to an more non specific date (from memory) commencing around middle of this week.
Whether AVCT were sufficiently progressed in validation, tech transfer etc or not, and whether they were able to submit a tender application or not will have no bearing on the outcome should they announce a test or perhaps two tests that provide the solution that all governments are looking for. The result will be outstanding if/when they produce the goods....simple.
@tomvisual
Duplicate tenders being listed is not unusual...for example, I think it has already been noted and agreed that the £912m tender is listed in duplicate with different dates and references, so just as likely that the £496m Innova award is also a duplicate
I'm very surprised at the adverse reactions to what is clearly a bit of a joke. Does anyone seriously think that anyone would have believed for one minute that the BBC and/or BJ would have created the piece that included Avacta in the same shot...no chance.
Well, at least no chance until such time as we have completed the test and Boris insists on standing front and centre with our test in his hand.
Also worth bearing in mind that the Tender rules are such that the top 5 candidates get 30%, 30%, 20%, 10% and 10% respectively. If either of the parties cannot satisfy/provide the volume dictated by their % then that difference goes to the highest remaining candidate. However any one candidate can only get a max 40% of the tender.
Essentially, we just need to ensure that we get our test in the running if Innova is the best quality competition.
I'm all for vaccines, but these big Pharmas need to play fair and not cut corners.
https://www.bloomberg.com/news/articles/2020-11-24/astra-vaccine-s-90-efficacy-in-covid-came-in-younger-population
Very odd that so many first time posters feel the intense need to advise everyone that it's their first post and their first account before then asking for an explanation of something they have doubts about. Very strange indeed. Lol.